Powder: -20°C for 3 years
In solvent: -80°C for 2 years
PRLX-93936 hcl is an analog of erastin and demonstrated synergistic effects against non-small cell lung cancer (NSCLC) cells with cisplatin.
Description | PRLX-93936 hcl is an analog of erastin and demonstrated synergistic effects against non-small cell lung cancer (NSCLC) cells with cisplatin. |
In vitro | Cotreatment with cisplatin and PRLX93936 induced ferroptosis, as evidenced by the upregulation of ROS, lipid peroxidation and Fe2+. Further investigation revealed that cotreatment with cisplatin and PRLX93936 inhibited GPX4 and that overexpression of GPX4 prevented cell death. Moreover, the Nrf2/Keap1 pathway also regulated the sensitivity to cisplatin and PRLX93936 in NSCLC cells. Nrf2 silencing increased this sensitivity while inhibition of Keap1 attenuated it[1]. |
Synonyms | PRLX-93936 hcl(903499-49-0 Free base) |
Molecular Weight | 437.37 |
Formula | C21H26Cl2N4O2 |
CAS No. | 1094210-96-4 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 50.00mg/ml
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PRLX-93936 HCL 1094210-96-4 NF-Κb Metabolism Immunology/Inflammation Cell Cycle/Checkpoint Apoptosis Ferroptosis Reactive Oxygen Species PRLX93936 HCL PRLX 93936 HCL PRLX-93936 hcl(903499-49-0 Free base) Inhibitor inhibitor inhibit